2023-04-04 14:00:00 ET
Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating billion-dollar revenue for years, thanks to its portfolio of cystic fibrosis (CF) drugs. In fact, Vertex is the global leader in CF treatment and likely to hang onto that position for quite some time. But soon, the company may expand into a completely different area -- and that potential product could become a blockbuster .
The biotech giant and partner CRISPR Therapeutics (NASDAQ: CRSP) aim to bring exa-cel, a gene editing treatment for blood disorders, to market. The companies just took one key step closer to their goal: They completed exa-cel's U.S. regulatory submission.
Does this mean now is a good time to buy Vertex shares? Let's find out.
For further details see:
Vertex Is 1 Step Closer to Bringing a New Blockbuster to Market. Time to Buy?